Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update (2022)

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke – Drugs In Development, 2022, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 38, 34, 3, 11, 152, 24 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 34 and 5 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • 4B Technologies (Suzhou) Co Ltd

    AbbVie Inc

    Acticor Biotech SAS

    advanceCor GmbH

    Advanced BioMatrix Inc

    AegisCN LLC

    Aegle Therapeutics Corp

    Akome Biotech Ltd

    AlaMab Therapeutics Inc

    Algernon Pharmaceuticals Inc

    Allife Medical Science and Technology Co Ltd

    Anavex Life Sciences Corp

    Angion Biomedica Corp

    Ankasa Regenerative Therapeutics Inc

    Annovis Bio Inc

    Anthos Therapeutics Inc

    AntiRadical Therapeutics LLC

    Apellis Pharmaceuticals Inc

    Aposcience AG

    APstem Therapeutics Inc

    APT Therapeutics Inc

    AptaTargets SL

    Argenica Therapeutics Ltd


    ArmaGen Inc

    ArunA Bio Inc

    Asdera LLC

    Asha Therapeutics LLC

    AstraZeneca Plc

    Astrocyte Pharmaceuticals Inc

    Athersys Inc

    Avilex Pharma ApS

    Axolo Pharma Inc

    Band Therapeutics LLC

    Basking Biosciences Inc

    Bayer AG

    Baylx Inc

    Beijing Darwin Cell Biotechnology Co Ltd

    Beijing Yinfeng Dingcheng Bioengineering Co Ltd

    Bilix Co Ltd

    Bio-Synectics Inc

    Biogen Inc

    Biosios (Beijing) Biotechnology Co Ltd

    Bioxytran Inc

    Bolden Therapeutics Inc

    Bopin (Shanghai) Biomedical Technology Co Ltd

    Brain-Gen LLC

    Bristol-Myers Squibb Co

    Cenyx Biotech Inc

    CHA Biotech Co Ltd

    Changzhou Qianhong Bio-Pharma Co Ltd

    Chengdu Aoda Biotechnology Co Ltd

    Chengdu Shibeikang Biomedical Technology Co Ltd

    China Resources Emde Biological Pharmaceutical Co Ltd

    Clinuvel Pharmaceuticals Ltd

    Cogentis Therapeutics Inc

    CohBar Inc

    Constant Therapeutics LLC

    Creative Medical Technology Holdings Inc

    Crioestaminal Saude e Tecnologia SA

    Daewoong Pharmaceutical Co Ltd

    Deha Pharmaceutical LLC

    Diapin Therapeutics LLC

    DR.Noah Biotech Inc

    Edvince AB

    Egret Therapeutics Inc

    Eight Plus One Pharmaceutical Co Ltd

    EIP Pharma LLC

    Elevian Inc

    Emerald Organic Products Inc

    Epigen Biosciences Inc

    Epygen Biotech Pvt Ltd

    Ever Supreme Bio Technology Co Ltd

    Evgen Pharma Plc

    Exscien Corp

    F. Hoffmann-La Roche Ltd

    Fortuna Fix Inc

    Freeox Biotech SL

    FUJIFILM Toyama Chemical Co Ltd

    GABA Therapeutics Inc

    Genentech USA Inc

    Genervon Biopharmaceuticals LLC

    Glucox Biotech AB

    GNT Pharma Co Ltd

    Guangzhou Cellprotek Pharmaceutical Co Ltd

    Guangzhou Magpie Pharmaceutical Co Ltd

    Guangzhou Recomgen Biotech Co Ltd

    Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd

    Gwoxi Stem Cell Applied Technology Co Ltd

    Haimen Shengyuan Stem Cell Technology Co Ltd

    Hefei Medical & Pharmaceutical Co Ltd

    Help Therapeutics

    Hemostemix Inc

    Henan Genuine Biotech Co Ltd

    Hibernaid Inc

    Hillhurst Biopharmaceuticals Inc

    Hopstem Biotechnology LLC

    Hoth Therapeutics Inc

    Immunwork Inc

    Imstem Biotechnology Inc

    Infensa Bioscience Pty Ltd

    Inflammx Therapeutics Inc

    Instituto Biomar SA

    International Stem Cell Corp

    Io Therapeutics Inc

    IPCA Laboratories Ltd

    Jeil Pharmaceutical Co Ltd

    Jiangsu Aidea Pharmaceutical Co Ltd

    Jiangsu Carephar Pharmaceutical Co Ltd

    Jiangsu Ouwei Pharmaceutical Co Ltd

    Jiangsu Wangao Pharmaceutical Co Ltd

    JT Pharmaceuticals Inc

    Kai Nuo Bio Sci Co Ltd

    Les Laboratoires Servier SAS

    Lixte Biotechnology Holdings Inc

    LTT Bio-Pharma Co Ltd

    Lumosa Therapeutics Co Ltd

    Lys Therapeutics SAS

    M et P Pharma AG

    M3 Therapeutics Inc

    Mapreg SAS

    Marizyme Inc

    MD Healthcare Inc

    Meridigen Biotech Co Ltd

    MetiMedi Pharmaceuticals Co Ltd

    Mitoconix Bio Ltd

    Modulation Therapeutics Inc

    NA Vaccine Research Institute Co Ltd

    Nanjing Ningdan New Drug Technology Co Ltd

    NC Medical Research Inc

    NervGen Pharma Corp

    NeuExcell Therapeutics Inc

    Neuraly Inc

    Neuren Pharmaceuticals Ltd

    Neurevo GmbH

    Neurexis Therapeutics Inc

    NeurExo Sciences LLC

    Neurodon LLC

    NeuroNascent Inc

    Neurondawn pharmaceutical Co Ltd

    NeurOp Inc

    Neurophyxia BV

    NeuroTrauma Sciences LLC

    New World Laboratories Inc

    Nipro Corp

    NoNO Inc

    Novago Therapeutics AG

    Novartis AG

    NuvOx Pharma LLC

    Nyrada Inc

    Oasis Pharmaceuticals LLC

    Omniox Inc

    OTR3 SAS

    Oxitope Pharma BV

    Palisade Bio

  • Inc

    Paracelsus Neuroscience I LLC

    Pharmadrug Inc

    Pharmagenesis Inc

    PharmaTher Holdings Ltd

    PharmatrophiX Inc

    Pharmazz Inc

    Pharmicell Co Ltd

    Pharming Group NV

    Phoenix Biotechnology Inc

    PhytoHealth Corp

    Prediction BioSciences SAS

    Primary Peptides Inc

    Prolong Pharmaceuticals LLC

    Protheragen Inc

    Q Therapeutics Inc

    Q32 Bio Inc

    Qingdao Primedicine Pharmaceutical Technology Co Ltd

    Regenera Pharma Ltd

    Regeneron Pharmaceuticals Inc

    RegeneRx Biopharmaceuticals Inc

    Reliance Life Sciences Pvt Ltd

    Remedium Bio Inc

    ReNetX Bio

    ReNeuron Group Plc

    Revalesio Corp

    Revive Therapeutics Ltd

    Rubicon Biotechnology Inc

    S&E Bio Co Ltd

    S.Biomedics Co Ltd

    Saillant Therapeutics BV

    Saje Pharma LLC

    SanBio Co Ltd

    Saneron CCEL Therapeutics Inc

    Saniona AB

    Sansho Co Ltd

    Savara Inc

    Sentan Pharma Inc

    Serenity Bioworks Inc

    Shanghai Hutchison Pharmaceuticals Ltd

    Shanghai SIMR Biotech Co Ltd

    Shanghai Zhimeng Biopharma Inc

    Shijiazhuang Yiling Pharmaceutical Co Ltd

    Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd

    Shin Poong Pharm Co Ltd

    Shionogi & Co Ltd

    Silver Creek Pharmaceuticals Inc

    Simcere Pharmaceutical Co Ltd

    SL Bigen Co Ltd

    SNJ Pharma Inc

    Stemedica Cell Technologies Inc

    Stemetix Inc

    Stream Biomedical Inc

    SunBio Inc

    Suzhou Auzone Biological Technology Co Ltd

    Suzhou Pharmavan Cancer Research Center Co Ltd

    Synaptogenix Inc

    TagCyx Biotechnologies

    TargED Biopharmaceuticals BV

    Tasly Pharmaceutical Group Co Ltd

    Techfields Pharma Co Ltd

    The Cell Factory BVBA

    Theertha Biopharma Pvt Ltd

    TheraSource LLC

    Theratome Bio Inc

    Thrombolytic Science International LLC

    TikoMed AB

    Translational Sciences Inc

    TrueBinding Inc

    Valin Technologies Ltd

    Vanworld Pharmaceutical (Rugao) Company Ltd

    Vect-Horus SAS

    Venturis Therapeutics Inc

    Verseon Corp

    Virogenomics BioDevelopment Inc

    Virtici LLC

    Vitro Biopharma Inc

    Vivazome Therapeutics Pty Ltd

    XBiotech Inc

    Xonovo Inc

    Yantai YenePharma Co Ltd

    YouCare Pharmaceutical Group Co Ltd

    Zensun (Shanghai) Sci & Tech Co Ltd

    Zhejiang Ausun Pharmaceutical Co Ltd

    Zhittya Genesis Medicine Inc

    Zocere Inc

    ZyVersa Therapeutics Inc

    ZZ Biotech LLC

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Stroke – Overview

Stroke – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Stroke – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Stroke – Companies Involved in Therapeutics Development

Stroke – Drug Profiles

Stroke – Dormant Projects

Stroke – Discontinued Products

Stroke – Product Development Milestones

Featured News & Press Releases

Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors




Secondary Research

Primary Research

Expert Panel Validation

Contact Us


List of Tables

List of Tables

Number of Products under Development for Stroke, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Products under Development by Universities/Institutes, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Stroke – Dormant Projects, 2022

Stroke – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Stroke, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

You might also like

Latest Posts

Article information

Author: Carlyn Walter

Last Updated: 08/05/2022

Views: 5685

Rating: 5 / 5 (70 voted)

Reviews: 85% of readers found this page helpful

Author information

Name: Carlyn Walter

Birthday: 1996-01-03

Address: Suite 452 40815 Denyse Extensions, Sengermouth, OR 42374

Phone: +8501809515404

Job: Manufacturing Technician

Hobby: Table tennis, Archery, Vacation, Metal detecting, Yo-yoing, Crocheting, Creative writing

Introduction: My name is Carlyn Walter, I am a lively, glamorous, healthy, clean, powerful, calm, combative person who loves writing and wants to share my knowledge and understanding with you.